Loading
Latest filing published 19 Aug 2026 for 에이프릴바이오.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
진홍국 is a declared insider of 에이프릴바이오 (board member), with filings sourced from DART (FSS). Over a trading history stretching from 16 January 2026 to 19 August 2026, the count stands at 4 filings.
On the open market, the record shows 3 purchases worth €125k and 1 sale. No amount is published for 3 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The record was last updated on 19 August 2026 with an open-market purchase in 에이프릴바이오. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.